Intra-Cellular Therapies’ (ITCI) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report published on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has a $132.00 target price on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the company. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Friday, March 28th. They issued a “hold” rating on the stock. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Finally, Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $106.23.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $131.91 on Wednesday. The company has a 50 day simple moving average of $129.43 and a 200 day simple moving average of $100.82. Intra-Cellular Therapies has a 1 year low of $64.09 and a 1 year high of $131.98. The firm has a market cap of $14.05 billion, a PE ratio of -151.62 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. As a group, research analysts anticipate that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Several hedge funds and other institutional investors have recently modified their holdings of ITCI. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 133 shares in the last quarter. Wellington Management Group LLP raised its holdings in Intra-Cellular Therapies by 1.6% during the fourth quarter. Wellington Management Group LLP now owns 1,033,743 shares of the biopharmaceutical company’s stock worth $86,338,000 after buying an additional 16,096 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Intra-Cellular Therapies by 36.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,010 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 3,200 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Intra-Cellular Therapies during the fourth quarter valued at about $7,951,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $186,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.